Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 9;20(11):1429-1438.
doi: 10.1093/neuonc/noy032.

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges

Stephen J Bagley  1 , Arati S Desai  1 , Gerald P Linette  1   2 , Carl H June  1   2 , Donald M O'Rourke  1   3
Affiliations
Review

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges

Stephen J Bagley et al. Neuro Oncol. .

Abstract

In patients with certain hematologic malignancies, the use of autologous T cells genetically modified to express chimeric antigen receptors (CARs) has led to unprecedented clinical responses. Although progress in solid tumors has been elusive, recent clinical studies have demonstrated the feasibility and safety of CAR T-cell therapy for glioblastoma. In addition, despite formidable barriers to T-cell localization and effector function in glioblastoma, signs of efficacy have been observed in select patients. In this review, we begin with a discussion of established obstacles to systemic therapy in glioblastoma and how these may be overcome by CAR T cells. We continue with a summary of previously published CAR T-cell trials in GBM, and end by outlining the key therapeutic challenges associated with the use of CAR T cells in this disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Theoretical study schema for a CAR T-cell trial in recurrent GBM. Proposed scientific and clinical questions for future studies are listed for each component.
See this image and copyright information in PMC

References

    1. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–398. - PMC - PubMed
    1. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494–502. - PMC - PubMed
    1. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 2001;8(21):1601–1608. - PubMed
    1. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods. 2001;248(1-2):67–76. - PubMed
    1. Hombach A, Wieczarkowiecz A, Marquardt T, et al. . Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001;167(11):6123–6131. - PubMed

MeSH terms

Substances